$MD
Pediatrix Medical Group, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022021526 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $513.8M $489.9M
YoY Change 3.07% -0.62%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $417.6M $400.7M
YoY Change 6.63% 1.29%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $9.136M $8.956M
YoY Change 16.25% 9.88%
% of Gross Profit
Operating Expenses $458.2M $442.5M
YoY Change 7.2% 1.93%
Operating Profit $47.39M
YoY Change -19.4%
Interest Expense -$8.214M $9.516M
YoY Change -43.31% -45.92%
% of Operating Profit 20.08%
Other Income/Expense, Net -$8.528M
YoY Change -44.48%
Pretax Income $27.82M $38.86M
YoY Change -48.01% -10.53%
Income Tax $3.824M $10.05M
% Of Pretax Income 13.74% 25.87%
Net Earnings $29.66M $30.73M
YoY Change -37.58% -0.22%
Net Earnings / Revenue 5.77% 6.27%
Basic Earnings Per Share $0.37
Diluted Earnings Per Share $0.36 $0.37
COMMON SHARES
Basic Shares Outstanding 83.07M 84.35M
Diluted Shares Outstanding 82.78M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $103.1M $100.1M
YoY Change -78.84% -78.08%
Cash & Equivalents $9.824M $8.668M
Short-Term Investments $93.24M $91.40M
Other Short-Term Assets $13.26M $9.899M
YoY Change -29.82% -75.07%
Inventory
Prepaid Expenses $14.88M $9.664M
Receivables $296.8M $294.4M
Other Receivables $0.00 $9.729M
Total Short-Term Assets $428.0M $423.7M
YoY Change -49.08% -46.23%
LONG-TERM ASSETS
Property, Plant & Equipment $73.29M $71.66M
YoY Change 4.47% -1.23%
Goodwill $1.530B $1.532B
YoY Change 1.63% 2.36%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $123.2M $117.7M
YoY Change -5.99% -9.51%
Total Long-Term Assets $1.920B $1.908B
YoY Change 2.01% 2.7%
TOTAL ASSETS
Total Short-Term Assets $428.0M $423.7M
Total Long-Term Assets $1.920B $1.908B
Total Assets $2.348B $2.332B
YoY Change -13.76% -11.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $31.86M $27.14M
YoY Change -13.07% -21.03%
Accrued Expenses $364.0M $302.0M
YoY Change -3.5% -16.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $14.90M $14.92M
YoY Change 498.31% 483.46%
Total Short-Term Liabilities $427.0M $351.7M
YoY Change -0.09% -11.54%
LONG-TERM LIABILITIES
Long-Term Debt $636.4M $731.0M
YoY Change -36.51% -27.08%
Other Long-Term Liabilities $39.41M $42.50M
YoY Change -6.9% 0.93%
Total Long-Term Liabilities $39.41M $42.50M
YoY Change -6.9% 0.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $427.0M $351.7M
Total Long-Term Liabilities $39.41M $42.50M
Total Liabilities $1.456B $1.473B
YoY Change -20.24% -18.17%
SHAREHOLDERS EQUITY
Retained Earnings -$89.06M -$118.7M
YoY Change -42.68% -41.49%
Common Stock $984.4M $981.5M
YoY Change -6.29% -6.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $891.6M $858.7M
YoY Change
Total Liabilities & Shareholders Equity $2.348B $2.332B
YoY Change -13.76% -11.87%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income $29.66M $30.73M
YoY Change -37.58% -0.22%
Depreciation, Depletion And Amortization $9.136M $8.956M
YoY Change 16.25% 9.88%
Cash From Operating Activities $98.69M $83.33M
YoY Change 123.09% 36.38%
INVESTING ACTIVITIES
Capital Expenditures $9.058M -$6.947M
YoY Change -385.92% -34.12%
Acquisitions
YoY Change
Other Investing Activities -$2.183M $859.0K
YoY Change -82.42% -102.8%
Cash From Investing Activities -$11.24M -$6.088M
YoY Change -27.87% -85.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -86.29M -82.66M
YoY Change -10559.27% 63000.76%
NET CHANGE
Cash From Operating Activities 98.69M 83.33M
Cash From Investing Activities -11.24M -6.088M
Cash From Financing Activities -86.29M -82.66M
Net Change In Cash 1.156M -5.420M
YoY Change -96.08% -127.43%
FREE CASH FLOW
Cash From Operating Activities $98.69M $83.33M
Capital Expenditures $9.058M -$6.947M
Free Cash Flow $89.63M $90.28M
YoY Change 89.07% 26.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.98
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
0
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
8621000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
md Repayments Of Long Term Capital Lease Obligation
RepaymentsOfLongTermCapitalLeaseObligation
2176000
md Repayments Of Long Term Capital Lease Obligation
RepaymentsOfLongTermCapitalLeaseObligation
1796000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4220000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5611000
md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
83069757
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8668000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
387391000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
91396000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
99715000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
294351000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
301775000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9664000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
18538000
CY2022Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
9729000
CY2021Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
14249000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
9899000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
18896000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
423707000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
840564000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
71656000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70154000
CY2022Q3 us-gaap Goodwill
Goodwill
1532092000
CY2021Q4 us-gaap Goodwill
Goodwill
1505430000
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
19534000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
21565000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
11074000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
351694000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
427366000
CY2022Q3 us-gaap Line Of Credit
LineOfCredit
95000000
CY2021Q4 us-gaap Line Of Credit
LineOfCredit
0
CY2022Q3 md Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
69346000
CY2021Q4 md Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
65461000
CY2022Q3 md Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit
LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
636004000
CY2022Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
97899000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
88344000
CY2021Q4 md Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit
LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
1002258000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45559000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
41396000
CY2022Q3 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
262626000
CY2021Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
271093000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
117723000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
131028000
CY2022Q3 us-gaap Assets
Assets
2331957000
CY2021Q4 us-gaap Assets
Assets
2722546000
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3667538
dei Entity Address Address Line1
EntityAddressAddressLine1
1301 Concord Terrace
dei Entity Address City Or Town
EntityAddressCityOrTown
Sunrise
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33323
dei City Area Code
CityAreaCode
954
dei Local Phone Number
LocalPhoneNumber
384-0175
dei Security12b Title
Security12bTitle
Common Stock, par value $.01 per share
dei Trading Symbol
TradingSymbol
MD
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.44
dei Entity Small Business
EntitySmallBusiness
false
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0000893949
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-12111
dei Entity Registrant Name
EntityRegistrantName
Pediatrix Medical Group, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
CY2022Q3 md Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current
AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
306460000
CY2021Q4 md Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current
AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
394118000
CY2022Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
14919000
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
2490000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
22654000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
19684000
CY2022Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
7661000
CY2022Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
39904000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
41409000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
42503000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
42332000
CY2022Q3 us-gaap Liabilities
Liabilities
1473290000
CY2021Q4 us-gaap Liabilities
Liabilities
1825854000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83006000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83006000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86423000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86423000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
830000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
864000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
980659000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1049696000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4100000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1317000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-118722000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-155390000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
858667000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
896487000
CY2022Q3 us-gaap Minority Interest
MinorityInterest
0
CY2021Q4 us-gaap Minority Interest
MinorityInterest
205000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
858667000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
896692000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2331957000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2722546000
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
489915000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
492949000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1458177000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1412661000
CY2022Q3 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
342850000
CY2021Q3 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
328759000
md Practice Salaries And Benefits
PracticeSalariesAndBenefits
1016762000
md Practice Salaries And Benefits
PracticeSalariesAndBenefits
964806000
CY2022Q3 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
31857000
CY2021Q3 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
26122000
md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
90189000
md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
72516000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
57888000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
66892000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
180340000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
204376000
CY2022Q3 us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
0
CY2021Q3 us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
0
us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
0
us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
7280000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8956000
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8151000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26500000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
24288000
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
977000
CY2021Q3 us-gaap Restructuring Charges
RestructuringCharges
4232000
us-gaap Restructuring Charges
RestructuringCharges
7736000
us-gaap Restructuring Charges
RestructuringCharges
19042000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
442528000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
434156000
us-gaap Operating Expenses
OperatingExpenses
1321527000
us-gaap Operating Expenses
OperatingExpenses
1277748000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
47387000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
58793000
us-gaap Operating Income Loss
OperatingIncomeLoss
136650000
us-gaap Operating Income Loss
OperatingIncomeLoss
134913000
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
617000
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
1686000
us-gaap Investment Income Net
InvestmentIncomeNet
2336000
us-gaap Investment Income Net
InvestmentIncomeNet
11829000
CY2022Q3 us-gaap Interest Expense
InterestExpense
9516000
CY2021Q3 us-gaap Interest Expense
InterestExpense
17595000
us-gaap Interest Expense
InterestExpense
29743000
us-gaap Interest Expense
InterestExpense
52119000
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-57016000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-14532000
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
371000
CY2021Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
550000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1319000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1622000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8528000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15359000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-83104000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-53200000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
38859000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
43434000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
53546000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
81713000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10051000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11594000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14982000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14002000
CY2022Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
28808000
CY2021Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
31840000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
38564000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
67711000
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
1920000
CY2021Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-1052000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-1892000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
15716000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
30728000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
30788000
us-gaap Profit Loss
ProfitLoss
36672000
us-gaap Profit Loss
ProfitLoss
83427000
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-0
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-7000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-4000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-21000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
30728000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
30795000
us-gaap Net Income Loss
NetIncomeLoss
36676000
us-gaap Net Income Loss
NetIncomeLoss
83448000
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.35
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.37
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.46
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.80
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.35
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.37
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.45
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.79
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.02
CY2021Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.02
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.18
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.02
CY2021Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.01
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.02
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.18
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.37
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.36
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.37
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.97
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82126000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85065000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
84122000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
84754000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82776000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86096000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84821000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85759000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
896692000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21188000
CY2022Q1 md Dissolution Of And Net Income Loss Attributable To Noncontrolling Interest
DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest
-203000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2668000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1174000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4435000
CY2022Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1166000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
877076000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
27136000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1234000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1664000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5186000
CY2022Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
64398000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
845430000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
30728000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1515000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1381000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4120000
CY2022Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
21477000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
858667000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
747717000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
17642000
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-8000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1133000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1042000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3717000
CY2021Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1994000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
766983000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
35011000
CY2021Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-6000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
116000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1536000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5735000
CY2021Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
251000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
809124000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
30795000
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-7000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-290000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3034000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5495000
CY2021Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2474000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
845677000
us-gaap Net Income Loss
NetIncomeLoss
36676000
us-gaap Net Income Loss
NetIncomeLoss
83448000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-1892000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
15716000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26500000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
24288000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1346000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3520000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-57016000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-14532000
us-gaap Share Based Compensation
ShareBasedCompensation
12891000
us-gaap Share Based Compensation
ShareBasedCompensation
14947000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-8702000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-30191000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2379000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1639000
us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
0
us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
7280000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
501000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
42027000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-22709000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-26391000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-11160000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-9412000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-76439000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5316000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-799000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
16391000
us-gaap Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve
IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
7360000
us-gaap Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve
IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
557000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-10309000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-19817000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
80019000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
38718000
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-11764000
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-6217000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
68255000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
32501000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
28167000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
19550000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
14938000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
11431000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
15889000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
15495000
us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
20650000
us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
29081000
us-gaap Proceeds From Sale Of Buildings
ProceedsFromSaleOfBuildings
0
us-gaap Proceeds From Sale Of Buildings
ProceedsFromSaleOfBuildings
24728000
md Strategic Investments
StrategicInvestments
0
md Strategic Investments
StrategicInvestments
20000000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-2153000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-45713000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-39839000
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
0
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
2350000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-45713000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37489000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
674500000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
579500000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0
md Payments To Term Loan
PaymentsToTermLoan
6250000
md Payments To Term Loan
PaymentsToTermLoan
0
us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
1046880000
us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
759848000
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
650000000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
87041000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
4719000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
483000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-189000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-401265000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-760941000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-378723000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-765929000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
387391000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1123843000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8668000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
357914000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
91396000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
99715000
CY2022Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1499499000
CY2021Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1393584000
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1205148000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1091809000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
294351000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
301775000
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
489915000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
492949000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1458177000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1412661000
CY2022Q3 md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
CY2021Q3 md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
CY2022Q3 us-gaap Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
26700000
CY2022Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
2300000
CY2022Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
2200000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
27136000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
36645000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
84754000
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
142515000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
213974000
CY2022Q3 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
37191000
CY2021Q4 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
34994000
CY2022Q3 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
32072000
CY2021Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
37729000
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
3520000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
29052000
CY2022Q3 md Accrued Contingent Consideration
AccruedContingentConsideration
2022000
CY2021Q4 md Accrued Contingent Consideration
AccruedContingentConsideration
0
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
62004000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
41724000
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
306460000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
394118000
CY2021 md Increase Decrease In Accrued Salaries And Bonuses
IncreaseDecreaseInAccruedSalariesAndBonuses
71500000
CY2022Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.05375
us-gaap Debt Instrument Frequency Of Periodic Payment
DebtInstrumentFrequencyOfPeriodicPayment
payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022
us-gaap Debt Instrument Description
DebtInstrumentDescription
Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions
CY2022Q3 md Purchase Price
PurchasePrice
1.01
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2027-02-11
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82126000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85065000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
84122000
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
650000
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1031000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
699000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1005000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82776000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86096000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84821000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85759000
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1000
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
273000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10000
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4100000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12900000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5500000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15000000.0
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0
CY2018Q3 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
500000000.0
CY2021Q4 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
94000000.0
CY2022Q3 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
4400000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
87000000.0

Files In Submission

Name View Source Status
0000950170-22-021526-index-headers.html Edgar Link pending
0000950170-22-021526-index.html Edgar Link pending
0000950170-22-021526.txt Edgar Link pending
0000950170-22-021526-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
md-20220930.htm Edgar Link pending
md-20220930.xsd Edgar Link pending
md-ex31_1.htm Edgar Link pending
md-ex31_2.htm Edgar Link pending
md-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
md-20220930_cal.xml Edgar Link unprocessable
md-20220930_def.xml Edgar Link unprocessable
md-20220930_lab.xml Edgar Link unprocessable
md-20220930_pre.xml Edgar Link unprocessable
md-20220930_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable